Issue 60, 2015
From the journal:

RSC Advances

Hyaluronate–Flt1 peptide conjugate/epirubicin micelles for theranostic application to liver cancers†

Ki Su Kim,a   Sung Woo Hong,b   Hyemin Kim,c   Minsoo Cho,c   Seonghoon Kim,d   Wonhee Hur,b   Seok Hyun Yun,a   Seung Kew Yoonb  and  Sei Kwang Hahn*c  

* Corresponding authors

a Wellman Center for Photomedicine, Massachusetts General Hospital and Harvard Medical School, 65 Landsdowne St. UP-525, Cambridge, Massachusetts 02139, USA

b The Catholic University Liver Research Center and WHO Collaborating Center of Viral Hepatitis, The Catholic University of Korea, 505 Banpo-dong, Seocho-gu, Seoul 137-701, Republic of Korea

c Department of Materials Science and Engineering, Pohang University of Science and Technology (POSTECH), 77 Cheongam-Ro, Nam-gu, Pohang, Gyeongbuk 790-784, Republic of Korea
E-mail: skhanb@postech.ac.kr
Fax: +82 54 279 2399
Tel: +82 54 279 2159

d Graduate School of Nanoscience and Technology, Korea Advanced Institute of Science and Technology, 291 Daehak-ro, Yuseong-gu, Daejeon 305-338, Republic of Korea

Abstract

Cancer theranostic systems using polymeric micelles are emerging for simultaneous diagnosis and therapy. In this work, we have developed hyaluronate (HA)–Flt1 peptide conjugate micelles encapsulating epirubicin for theranostic treatment of hepatocellular carcinoma. Intravital bioimaging without labelling and in vivo anti-tumor therapeutic effect clearly confirmed the feasibility of HA–Flt1 peptide conjugate/epirubicin micelles for target-specific theranostic treatment of liver cancers.

Graphical abstract: Hyaluronate–Flt1 peptide conjugate/epirubicin micelles for theranostic application to liver cancers

About
Cited by
Related
Download options Please wait...

Supplementary files

Article information

DOI
https://doi.org/10.1039/C5RA07464A
Article type
Communication
Submitted
24 Apr 2015
Accepted
22 May 2015
First published
22 May 2015
This article is Open Access
Creative Commons BY-NC license

RSC Adv., 2015,5, 48615-48618

Permissions

Request permissions

Hyaluronate–Flt1 peptide conjugate/epirubicin micelles for theranostic application to liver cancers

K. S. Kim, S. W. Hong, H. Kim, M. Cho, S. Kim, W. Hur, S. H. Yun, S. K. Yoon and S. K. Hahn, RSC Adv., 2015, 5, 48615 DOI: 10.1039/C5RA07464A

This article is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported Licence. You can use material from this article in other publications, without requesting further permission from the RSC, provided that the correct acknowledgement is given and it is not used for commercial purposes.

To request permission to reproduce material from this article in a commercial publication, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party commercial publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements